DK1027339T3 - Fremgangsmåde og reagenser til N-alkylering af ureider - Google Patents

Fremgangsmåde og reagenser til N-alkylering af ureider

Info

Publication number
DK1027339T3
DK1027339T3 DK98949706T DK98949706T DK1027339T3 DK 1027339 T3 DK1027339 T3 DK 1027339T3 DK 98949706 T DK98949706 T DK 98949706T DK 98949706 T DK98949706 T DK 98949706T DK 1027339 T3 DK1027339 T3 DK 1027339T3
Authority
DK
Denmark
Prior art keywords
ureas
alkylation
reagents
methoxymethyl
diphenylbarbituric
Prior art date
Application number
DK98949706T
Other languages
Danish (da)
English (en)
Inventor
Daniela Gutman
Hershel Herzog
Original Assignee
Taro Pharma Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharma Ind filed Critical Taro Pharma Ind
Application granted granted Critical
Publication of DK1027339T3 publication Critical patent/DK1027339T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C07D207/408—Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
DK98949706T 1997-10-02 1998-10-02 Fremgangsmåde og reagenser til N-alkylering af ureider DK1027339T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/942,636 US6093820A (en) 1997-10-02 1997-10-02 Method and reagents for N-alkylating ureides
PCT/US1998/020665 WO1999018084A1 (fr) 1997-10-02 1998-10-02 Procede et reactifs de n-alkylation d'ureides

Publications (1)

Publication Number Publication Date
DK1027339T3 true DK1027339T3 (da) 2004-05-03

Family

ID=25478386

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98949706T DK1027339T3 (da) 1997-10-02 1998-10-02 Fremgangsmåde og reagenser til N-alkylering af ureider
DK03011817T DK1342718T3 (da) 1997-10-02 1998-10-02 N-alkylerede ureider

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03011817T DK1342718T3 (da) 1997-10-02 1998-10-02 N-alkylerede ureider

Country Status (13)

Country Link
US (4) US6093820A (fr)
EP (2) EP1342718B1 (fr)
JP (2) JP4061018B2 (fr)
CN (2) CN1193019C (fr)
AT (2) ATE299500T1 (fr)
AU (1) AU758506B2 (fr)
CA (1) CA2304970C (fr)
DE (2) DE69830860T2 (fr)
DK (2) DK1027339T3 (fr)
ES (2) ES2243833T3 (fr)
IL (2) IL135284A (fr)
PT (2) PT1342718E (fr)
WO (1) WO1999018084A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093820A (en) 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
EP1485101A4 (fr) * 2002-01-30 2006-04-12 Taro Pharma Ind Derives d'acide barbiturique non sedatifs
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP4739760B2 (ja) * 2002-12-11 2011-08-03 タロー・ファーマシューティカル・インダストリーズ・リミテッド バルビツール酸誘導体を使用する運動障害の治療方法
ES2421139T3 (es) * 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
WO2006003651A2 (fr) 2004-07-02 2006-01-12 Taro Pharmaceutical Industries, Ltd Procede de preparation d'acide 1-methoxymethyl-5,5-diphenylbarbiturique
EP1625848A1 (fr) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition et procédé pour améliorer l'administration de l'acide 5,5-diphénylbarbiturique
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8853257B2 (en) 2005-11-21 2014-10-07 Mordechai Sharir Succinimide derivatives as ocular hypotensive agents
US20090318515A1 (en) * 2005-11-21 2009-12-24 Mordechai Sharir Succinimide derivatives as ocular hypotensive agents
EP2081576A4 (fr) * 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame Procédé d'amélioration de la biodisponibilité pour les barbituriques non sédatifs
AU2011320608A1 (en) 2010-10-27 2013-05-23 The Gillette Company Composition dispensing device comprising a non-foaming hydrating composition
US20120278179A1 (en) 2011-04-28 2012-11-01 Ray Campbell Systems and methods for deducing user information from input device behavior
MX2014001892A (es) 2011-08-16 2014-05-27 Gillette Co Dispositivo dispensador de composiciones que comprende una composicion hidratante.
SG10201803685TA (en) 2013-11-01 2018-06-28 Gillette Co Llc Shave care composition for a liquid dispensing razor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2673205A (en) 1951-02-13 1954-03-23 Ciba Pharm Prod Inc 3-disubstituted dioxopiperidines and the manufacture thereof
AR204518A1 (es) * 1973-02-28 1976-02-12 Kendall & Co Procedimiento para preparar n-mono(alcoximetil)fenobarbital
DE2622981A1 (de) * 1976-05-21 1977-12-08 Unisearch Ltd Verfahren zur herstellung von halogenalkylierten verbindungen
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
DE4028040A1 (de) * 1990-09-05 1992-03-12 Chemie Linz Deutschland Verfahren zur n-alkylierung von harnstoffen
DE19504623A1 (de) 1995-02-13 1996-08-14 Bayer Ag Verfahren zur Herstellung von N-substituierten cyclischen Imiden
US6184238B1 (en) 1996-12-26 2001-02-06 Nikken Chemicals Co., Ltd. N-hydroxyurea derivative and pharmaceutical composition containing the same
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
CA2331735A1 (fr) 1998-05-08 1999-11-18 Smithkline Beecham P.L.C. Derives de phenyluree et de (phenylthio)uree
JP2002516315A (ja) 1998-05-26 2002-06-04 ナチュラル ドラッグ サイエンシズ,リミティド ライアビリティ カンパニー 5−オキシミノバルビツール酸のn−置換誘導体
CA2306170A1 (fr) 2000-04-18 2001-10-18 Kenneth Curry Nouveaux derives amines et carboxyles de l'acide barbiturique
WO2002007729A1 (fr) 2000-07-26 2002-01-31 Taro Pharmaceutical Industries Ltd. Composes de barbiturique non sedatifs en tant qu'agents neuroprotecteurs

Also Published As

Publication number Publication date
DE69820895D1 (de) 2004-02-05
PT1027339E (pt) 2004-05-31
CN1273581A (zh) 2000-11-15
EP1027339A1 (fr) 2000-08-16
USRE38934E1 (en) 2006-01-10
AU758506B2 (en) 2003-03-20
US20040167358A1 (en) 2004-08-26
EP1027339B1 (fr) 2004-01-02
DE69830860T2 (de) 2006-04-27
IL165080A0 (en) 2005-12-18
DE69820895T2 (de) 2004-10-28
CA2304970A1 (fr) 1999-04-15
DE69830860D1 (de) 2005-08-18
WO1999018084A1 (fr) 1999-04-15
US6664262B2 (en) 2003-12-16
AU9597698A (en) 1999-04-27
EP1342718B1 (fr) 2005-07-13
ATE299500T1 (de) 2005-07-15
PT1342718E (pt) 2005-11-30
CN1699349A (zh) 2005-11-23
JP2001519334A (ja) 2001-10-23
JP2008101002A (ja) 2008-05-01
EP1342718A1 (fr) 2003-09-10
US6906079B2 (en) 2005-06-14
ES2243833T3 (es) 2005-12-01
CN1193019C (zh) 2005-03-16
IL135284A (en) 2005-11-20
ATE257153T1 (de) 2004-01-15
CA2304970C (fr) 2010-07-13
JP4061018B2 (ja) 2008-03-12
DK1342718T3 (da) 2005-09-26
US6093820A (en) 2000-07-25
US20030018080A1 (en) 2003-01-23
ES2214736T3 (es) 2004-09-16

Similar Documents

Publication Publication Date Title
ATE257153T1 (de) Verfahren und reagens fur n-alkylierte ureide
FI870113A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4,5,6-substioitujenN-(substituoitu-fenyyli)-2-pyrimidiiniamiinien valmistamiseksi
NO980255D0 (no) Antiparasittiske marcfortiner og paraherkvamider
NO994998D0 (no) Fusjonsproteiner
DE69919700D1 (de) Überbrückte indenopyrrolocarbazole
DE69637256D1 (de) Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
NO20005153L (no) Mutantprotein som har lavere allergenisk respons i mennesker og fremgangsmåter for konstruksjon, identifisering og fremstilling av slike proteiner
DK1054860T3 (da) Proces for syntesen af 1,3-dioler
NO20090583L (no) Terapi for alfa-galaktosidase A-mangel
DE69736840D1 (de) Synthese von nukleosiden und polynukleotiden
ATE376591T1 (de) Neisseria meningitidis antigene und zusammenstellungen
DK0930091T3 (da) Fremgangsmåde til behandling af röggasser
DK0911416T3 (da) Fremgangsmåde til fremstilling af protein
DK0923978T3 (da) Fremgangsmåde til behandling af röggas
DK0424350T3 (da) Derivater af 1,4-dideoxy-1,4-imino-D-mannitol
IS5542A (is) Tríazín efnasambönd til meðhöndlunar á truflunum í miðtaugakerfi (CNS)
DK0942992T3 (da) O-fucosyltransferase
DK0927766T3 (da) Enzymatisk fremgangsmåde til fremstilling af (S)-cyanhydriner
DK0554691T3 (da) Fremgangsmåde til behandling af røggas
DE69938144D1 (de) Antikörper-vermittelte verminderungsregulation von pflanzenproteinen
DK1086114T3 (da) Morfin-6-glucuronidsyntese
CY1109583T1 (el) Κυτοκινες θηλαστικων, αντιστοιχα αντιδραστηρια
ID21920A (id) 4-6-fluoro-(1h)-indol-3-il-1,2,3,6-tetrahidropirin tersubstitusi untuk pengobatan gangguan cns
DK1023292T3 (da) Fremgangsmåde til syntese af chlorpurinintermediater
EA199800090A1 (ru) Способ получения 4,6-диметокси-2-((феноксикарбонил)амино)пиримидина